Biotechnology News and Research RSS Feed - Biotechnology News and Research

GenomeNext completes whole genome sequencing analysis at unprecedented 1,000 genomes per day

GenomeNext completes whole genome sequencing analysis at unprecedented 1,000 genomes per day

GenomeNext, LLC, a leader in genomic data management and integrated analysis, announced today that, through the "Intel Heads In The Clouds Challenge on Amazon Web Services" with support from JHC Technology, and in conjunction with Nationwide Children's Hospital, has benchmarked whole genome sequencing analysis at an unprecedented 1,000 genomes per day. [More]
NantWorks, Sorrento collaborate to discover and develop novel anti-cancer immunotherapies

NantWorks, Sorrento collaborate to discover and develop novel anti-cancer immunotherapies

NantWorks, Inc. and Sorrento Therapeutics, Inc., announced today that they have entered into a binding agreement to initiate a global collaboration to discover and develop novel anti-cancer immunotherapies derived from Sorrento's proprietary G-MAB library against neoepitopes of tumor-specific antigens discovered using NantWorks' proprietary pan-omics based, precision medicine approach. [More]
Ruthigen, Pulmatrix sign definitive merger agreement

Ruthigen, Pulmatrix sign definitive merger agreement

Ruthigen, Inc., a biopharmaceutical company, and Pulmatrix, Inc., a Lexington, Massachusetts based clinical stage biotechnology company, announced today that on March 13, 2015, they have entered into a definitive merger agreement. [More]
Ember Therapeutics, Mariel Therapeutics sign definitive merger agreement

Ember Therapeutics, Mariel Therapeutics sign definitive merger agreement

Ember Therapeutics, Inc., a Boston-based biotechnology company dedicated to the discovery and development of novel obesity and diabetic related therapies, and Mariel Therapeutics, a privately held, New York-based biotechnology company developing targeted therapies for osteoarthritis and kidney fibrosis using Bone Morphogenetic Protein (BMP)-7, jointly announce today that they have entered into a definitive agreement to merge the two companies. [More]
More research needed to explore toxicity of cellulose nanocrystals, says Virginia Tech scientist

More research needed to explore toxicity of cellulose nanocrystals, says Virginia Tech scientist

Are cellulose nanocrystals harmful to human health? The answer might depend on the route of exposure, according to a review of the literature by a Virginia Tech scientist, but there have been few studies and many questions remain. [More]
Existing epilepsy drug reverses aMCI in elderly patients at risk for Alzheimer's disease

Existing epilepsy drug reverses aMCI in elderly patients at risk for Alzheimer's disease

A novel therapeutic approach for an existing drug reverses a condition in elderly patients who are at high risk for dementia due to Alzheimer's disease, researchers at Johns Hopkins University found. [More]
Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Benitec Biopharma, a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," today announced that the fourth patient in the company's Phase I/IIa dose escalation clinical trial of its lead program TT-034 for treating hepatitis C was dosed at the Duke Clinical Research Unit. [More]
Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

PharmaEssentia (Taipei, Taiwan) and AOP Orphan (Vienna, Austria) announce the completion of recruitment for the Phase III trial PROUD-PV to support global marketing of P1101 (Ropeginterferon alfa-2b), a novel, long-acting, mono-pegylated interferon for the first line treatment of polycythemia vera. [More]
LSDF announces new Matching grants to promote treatments for devastating medical conditions

LSDF announces new Matching grants to promote treatments for devastating medical conditions

The Life Sciences Discovery Fund today announced nearly $1 million in Matching grants to two Washington-based companies to promote translation of promising treatments for devastating medical conditions from the laboratory to the commercial marketplace. [More]
United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. [More]
TWi Biotechnology obtains Rare Disease Drug designation in Taiwan for use of AC-203 to treat EBS

TWi Biotechnology obtains Rare Disease Drug designation in Taiwan for use of AC-203 to treat EBS

TWi Pharmaceuticals, Inc. today announced that its fully owned subsidiary, TWi Biotechnology, Inc., has received the designation of Rare Disease Drug by Taiwan FDA for use of AC-203 to treat Epidermolysis Bullosa Simplex (EBS), and is eligible for applying for coverage under National Health Insurance Administration. [More]
Viagra can have anti-cancer, anti-Alzheimer's disease effects if used with new drugs

Viagra can have anti-cancer, anti-Alzheimer's disease effects if used with new drugs

Chaperone proteins play an important role in protein folding in human cells and in bacteria and are promising new targets for drugs to treat cancer and Alzheimer's disease and for novel antiviral drugs and antibiotics. How existing drugs such as Viagra or Cialis and a derivative of the drug Celebrex, for example, can reduce the activity of a specific chaperone protein, with the potential for anti-tumor and anti-Alzheimer's disease effects, is described in a Review article in DNA and Cell Biology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. [More]
Blood gas testing: an interview with David Stein, PhD, CEO, Point of Care, Siemens Healthcare Diagnostics

Blood gas testing: an interview with David Stein, PhD, CEO, Point of Care, Siemens Healthcare Diagnostics

The industry term ‘blood gas testing’ has come to mean the accurate measurement and reporting of a wide menu of blood parameters, all on a single platform. [More]
Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

CTI BioPharma Corp. and Baxter International Inc. today announced positive top-line results for the primary endpoint from PERSIST-1, the randomized, controlled Phase 3 registration clinical trial examining pacritinib, a next generation oral JAK2/FLT3 multikinase inhibitor, for the treatment of patients with primary or secondary myelofibrosis. [More]
Phico Therapeutics gets £2.25M Translation Award to develop SASPject PT4 antibiotic for E. coli, K. pneumoniae

Phico Therapeutics gets £2.25M Translation Award to develop SASPject PT4 antibiotic for E. coli, K. pneumoniae

Phico Therapeutics, a biotechnology company developing a novel platform technology for a new generation of antibiotics aimed at overcoming antibacterial resistance, has been awarded a £2.25M Translation Award by the Wellcome Trust to develop its SASPject PT4 antibiotic, aimed at Escherichia coli and Klebsiella pneumoniae. [More]
Study identifies 10 new cases of breast cancer in transgender veterans

Study identifies 10 new cases of breast cancer in transgender veterans

A study of breast cancer in transgender veterans has identified ten new cases, increasing the total number of published cases in both female-to-male and male-to-female transgender persons. [More]
New type of vaccine holds promise for prevention of genital herpes

New type of vaccine holds promise for prevention of genital herpes

Scientists at Albert Einstein College of Medicine of Yeshiva University have designed a new type of vaccine that could be the first-ever for preventing genital herpes--one of the most common sexually transmitted diseases, affecting some 500 million people worldwide. [More]
Key 'energy producing' protein plays a critical role in a good immune system

Key 'energy producing' protein plays a critical role in a good immune system

A good immune system relies on a key 'energy producing' protein in immune cells to develop immunity to vaccines and disease, an international team of scientists has found. [More]
New research challenges current theories of ageing

New research challenges current theories of ageing

Older brains may be more similar to younger brains than previously thought. [More]
Medical Diagnostic Laboratories now offers new HPV tests

Medical Diagnostic Laboratories now offers new HPV tests

Medical Diagnostic Laboratories, L.L.C., a CLIA-certified, CAP-accredited laboratory which specializes in high complexity, state-of-the-art, automated DNA-based molecular analyses, announces that it is now offering new Human Papillomavirus (HPV) testing which utilizes cutting edge technology, including next- generation DNA sequencing platforms. [More]
Advertisement
Advertisement